AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

11.320

+0.0500.44%

Volume:23.24K

Turnover:262.47K

Market Cap:566.11M

PE:14.71

High:11.400

Open:11.210

Low:11.210

Close:11.270

Loading ...

Overview Company News Filings

BRIEF-Clinuvel Pharmaceuticals Signs Distribution Agreement For Scenesse With Diligens Salud SA

Clinuvel Pharmaceuticals Appoints Argentinian Distributor for Porphyria Therapy

MT Newswires Live

Clinuvel Pharmaceuticals - Distribution Agreement for Scenesse With Diligens Salud Sa

THOMSON REUTERS

Exploring 3 High Growth Tech Stocks In Australia

Simply Wall St.

ASX Growth Stocks With Strong Insider Confidence

Simply Wall St.

BRIEF-Clinuvel Pharmaceuticals Says Scenesse Validated And Accepted For Review

Clinuvel Pharmaceuticals' New Drug Submission Under Health Canada Review

MT Newswires Live

Clinuvel Pharmaceuticals - Scenesse Validated and Accepted for Review Ahead of Health Canada's Target Validation Window

THOMSON REUTERS

Exploring High Growth Tech Stocks in Australia December 2024

Simply Wall St.

ASX Market Close: Telcos leads index lower | November 20, 2024

The Market Herald

Clinuvel in Talks with European Regulators Over Dosage Expansion for Metabolic Disorder Drug

MT Newswires Live

BRIEF-Clinuvel Pharmaceuticals Says Decision To Strategically Prioritise Three Key Clinical Programs

Clinuvel Pharmaceuticals to Prioritize Programs with Highest Likelihood of Regulatory Approval, Commercial Success

MT Newswires Live

Clinuvel Pharmaceuticals Ltd - Decision to Strategically Prioritise Three Key Clinical Programs

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CUV.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":11.32,"timestamp":1746771120000,"preClose":11.27,"halted":0,"volume":23237,"delay":0,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50009750,"eps":0.769445,"marketStatus":"Market Closed","change":0.05,"latestTime":"05-09 16:12:00 AEST","open":11.21,"high":11.4,"low":11.21,"amount":262465,"amplitude":0.016859,"askPrice":11.5,"askSize":500,"bidPrice":11.21,"bidSize":241,"shortable":3,"etf":0,"ttmEps":0.769445,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":11.27,"dividendRate":0.004417,"openAndCloseTimeList":[[1746748800000,1746770400000]],"volumeRatio":0.6353142525231966,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"14.22%","roe":"19.59%","lyrEps":0.7151,"volumeRatio":0.6353142525231966,"shares":50009750,"dividePrice":0.05,"high":11.4,"amplitude":0.016859,"preClose":11.27,"low":11.21,"week52Low":9.755,"pbRate":"2.61","psRate":"6.22","week52High":17.652,"institutionHeld":0,"latestPrice":11.32,"committee":-0.349528,"eps":0.769445,"divideRate":0.004417,"volume":23237,"delay":0,"ttmEps":0.769445,"open":11.21,"prevYearClose":12.06,"prevWeekClose":11.59,"prevMonthClose":11.36,"prevQuarterClose":11.46,"fiveDayClose":11.59,"twentyDayClose":10.66,"sixtyDayClose":11.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2504803976","title":"BRIEF-Clinuvel Pharmaceuticals Signs Distribution Agreement For Scenesse With Diligens Salud SA","url":"https://stock-news.laohu8.com/highlight/detail?id=2504803976","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504803976?lang=en_us&edition=fundamental","pubTime":"2025-01-17 09:23","pubTimestamp":1737077025,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Signs Distribution Agreement For Scenesse With Diligens Salud SAJan 17 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:DISTRIBUTION AGREEMENT FOR SCENESSE WITH DILIGENS SALUD SAFurther company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nFWN3OC0OP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2504292760","title":"Clinuvel Pharmaceuticals Appoints Argentinian Distributor for Porphyria Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2504292760","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504292760?lang=en_us&edition=fundamental","pubTime":"2025-01-17 07:56","pubTimestamp":1737071813,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) appointed specialty pharmaceutical firm Diligens Salud, part of the Scienza Group, to market and sell the Scenesse (afamelanotide) therapy in Argentina, according to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2504772926","title":"Clinuvel Pharmaceuticals -  Distribution Agreement for Scenesse With Diligens Salud Sa","url":"https://stock-news.laohu8.com/highlight/detail?id=2504772926","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504772926?lang=en_us&edition=fundamental","pubTime":"2025-01-17 06:24","pubTimestamp":1737066250,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC0OP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2500158639","title":"Exploring 3 High Growth Tech Stocks In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2500158639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500158639?lang=en_us&edition=fundamental","pubTime":"2025-01-03 12:07","pubTimestamp":1735877241,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a cautious start to the year, with the ASX 200 expected to open slightly lower amid global uncertainties and a weakening Aussie dollar, reflecting broader concerns about economic data and interest rate projections. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovative potential and resilience in fluctuating market conditions.Click here to see the full list of 60 stocks from our ASX High Growth Tech and AI Stocks screener.Underneath we present a selection of stocks filtered out by our screen.Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$602.36 million.Operations: Clinuvel Pharmaceuticals generates revenue primarily from its biopharmaceutical sector, amo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-3-high-growth-tech-040721425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7508","CUV.AU","FCL.AU","XAO.AU","BK7067","BK7016","MSB.AU","MESO","XKO.AU","XJO.AU","BK7501"],"gpt_icon":0},{"id":"2494099951","title":"ASX Growth Stocks With Strong Insider Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2494099951","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494099951?lang=en_us&edition=fundamental","pubTime":"2024-12-25 12:01","pubTimestamp":1735099291,"startTime":"0","endTime":"0","summary":"As the Australian stock market closes on a positive note with a modest gain in the ASX 200, investors are digesting the Reserve Bank of Australia's recent minutes that highlight persistent inflation concerns. In this environment, growth companies with high insider ownership can be particularly appealing as they often signal strong internal confidence and alignment with shareholder interests.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 95 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Accent Group shows potential as a growth company with high insider ownership. Its earnings are forecast to grow at 13.7% annually, outpacing the Australian market's growth rate of 12.5%. However, profit margins have declined from 6.2% to 4.1%. The stock is trading at a significant discount to its estimated fair value, suggesting potential undervaluation. Recent board appointments, including Dave Forsey as an Independen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-stocks-strong-insider-040131447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CUV.AU","BK7033","3DP.AU","BK7096","NWF.AU","BK7016","GYG.AU","BK7506","BK7021","BK7043","BK7084","FND.AU","AVA.AU","CCA.AU","BK7104","ACR.AU","XJO.AU","PLT.AU","BK7067","BTR.AU","BK7116","BK7508","XKO.AU","BK7093","IPX.AU","BK7137","SKS.AU","BK7023","XAO.AU","AX1.AU","BK7158"],"gpt_icon":1},{"id":"2493272831","title":"BRIEF-Clinuvel Pharmaceuticals Says Scenesse Validated And Accepted For Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2493272831","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493272831?lang=en_us&edition=fundamental","pubTime":"2024-12-23 09:28","pubTimestamp":1734917297,"startTime":"0","endTime":"0","summary":"Dec 23 (Reuters) - Clinuvel Pharmaceuticals Ltd :   * SCENESSE VALIDATED AND ACCEPTED FOR REVIEW AHEAD OF HEALTH CANADA'S TARGET VALIDATION WINDOWSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2493279189","title":"Clinuvel Pharmaceuticals' New Drug Submission Under Health Canada Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2493279189","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493279189?lang=en_us&edition=fundamental","pubTime":"2024-12-23 08:40","pubTimestamp":1734914404,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said its new drug submission to Health Canada for its photoprotective therapy Scenesse was validated and accepted for review ahead of the regulator's target validation window, according to a Monday filing with the Australian bourse.Scenesse was designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria an inherited metabolic disorder.The submission is now under review by Health Canada's Health Products and Food Branch, which has a 300-day target to complete its evaluation and issue a marketing authorization decision, the filing said. A decision is expected by the fourth quarter of 2025.Clinuvel Pharmaceuticals shares rose nearly 1% in morning trade Monday.Price : $11.90, Change: $+0.11, Percent Change: +0.93%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426412945.USD","LU0426417589.USD","BK7508","CUV.AU","LU0345774631.USD","LU0994945656.USD","LU2238339852.HKD","BK4125","LU1043141123.HKD","AUD","BK7067"],"gpt_icon":0},{"id":"2493208602","title":"Clinuvel Pharmaceuticals - Scenesse Validated and Accepted for Review Ahead of Health Canada's Target Validation Window","url":"https://stock-news.laohu8.com/highlight/detail?id=2493208602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493208602?lang=en_us&edition=fundamental","pubTime":"2024-12-23 06:17","pubTimestamp":1734905839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241222:nFWN3NL1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2489592109","title":"Exploring High Growth Tech Stocks in Australia December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2489592109","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489592109?lang=en_us&edition=fundamental","pubTime":"2024-12-05 12:07","pubTimestamp":1733371641,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a modest uptick with the ASX200 rising by 0.3% to 8,488 points, the IT sector stands out as a strong performer, climbing by 1.1%, amidst broader economic indicators suggesting potential volatility and constraints in the coming year. In this environment, identifying high-growth tech stocks requires careful consideration of their ability to thrive in dynamic conditions and leverage technological advancements to sustain momentum within an evolving market landscape.Click here to see the full list of 58 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: FINEOS Corporation Holdings plc develops and sells enterprise claims and policy management software for the employee benefits and life, accident, and health insurance industries globally, with a market capitalization of A$652.96 million.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-040721351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XJO.AU","XKO.AU","BK7067","MSB.AU","BK7508","BK7016","XAO.AU","CUV.AU","MESO","FCL.AU","BK7501"],"gpt_icon":0},{"id":"2484050159","title":"ASX Market Close: Telcos leads index lower | November 20, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484050159","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484050159?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:19","pubTimestamp":1732083540,"startTime":"0","endTime":"0","summary":"The ASX 200 closed down 0.57% at 8,326 points.Total wages and salaries paid by employers in Australia reached a record high of $103.7 billion in September, marking a 3.9% increase of $3.9 billion from the previous month, according to the Australian Bureau of Statistics.The Telecommunication sector was the biggest loser, down 1.5%, followed by Industrials, down 1.3% and Discretionary, down 1.1%.Health Care was best performer, gaining 0.25%, followed by Utilities, up 0.2%.Sparc Technologies  closed up 2.94% on news its teaming up withSantos to trial its anti-corrosion coating on assets in South Australia.Greenvale Energyclosed up 3.45% on news it will be expanding its uranium exploration portfolio with the acquisition of the Elkedra Uranium Project in the Northern Territory. The project is located 300km northeast of Alice Springs and 200km southeast of Tennant Creek, within the geologically significant Cambrian Georgina Basin.Webjet  closed down 9.78% after the online travel agent warned","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-telcos-leads-index-lower-november-20-2024-2024-11-20/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["GRE.AU","CUV.AU","WJL.AU","BK7508","BK7067","XJO.AU","SPN.AU","BK7095","BK7093","BK7507","XAO.AU","XKO.AU","STO.AU","BK7070","BK7036","PLT.AU","GRV.AU","BK7142"],"gpt_icon":0},{"id":"2484618080","title":"Clinuvel in Talks with European Regulators Over Dosage Expansion for Metabolic Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2484618080","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484618080?lang=en_us&edition=fundamental","pubTime":"2024-11-20 09:52","pubTimestamp":1732067538,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said it is in talks with the European Medicines Agency  to increase the recommended maximum dose of its drug Scenesse for adult patients with erythropoietic protoporphyria , according to a Wednesday filing with the Australian bourse.EPP is an inherited condition characterized by extreme photosensitivity and could lead to liver disease.The EMA's Pharmacovigilance Risk Assessment Committee will decide whether to maintain the existing drug label or expand it to up to six times per year, the filing said.The outcome is expected by the first quarter of 2025, according to the filing.Clinuvel Pharmaceuticals' shares were down more than 2% in recent Wednesday trade.Price : $13.30, Change: $-0.32, Percent Change: -2.39%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426417589.USD","CUV.AU","AUD","LU1043141123.HKD","BK4582","BK4125","EPP","LU0426412945.USD","BK7067","LU0345774631.USD","BK7508","LU0994945656.USD","LU2238339852.HKD"],"gpt_icon":0},{"id":"2484666409","title":"BRIEF-Clinuvel Pharmaceuticals Says Decision To Strategically Prioritise Three Key Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2484666409","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484666409?lang=en_us&edition=fundamental","pubTime":"2024-11-18 09:09","pubTimestamp":1731892159,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Says Decision To Strategically Prioritise Three Key Clinical ProgramsNov 18 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:DECISION TO STRATEGICALLY PRIORITISE THREE KE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MN0C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2484668044","title":"Clinuvel Pharmaceuticals to Prioritize Programs with Highest Likelihood of Regulatory Approval, Commercial Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2484668044","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484668044?lang=en_us&edition=fundamental","pubTime":"2024-11-18 08:04","pubTimestamp":1731888243,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) refocused resources to prioritize its three key areas of clinical development: vitiligo, adrenocorticotropic hormone, and porphyrias, according to a Monday filing wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","CUV.AU","LU0994945656.USD","BK7508","LU0426412945.USD","LU0426417589.USD","LU2238339852.HKD","AUD","LU1043141123.HKD","LU0345774631.USD","BK7067"],"gpt_icon":0},{"id":"2484865486","title":"Clinuvel Pharmaceuticals Ltd - Decision to Strategically Prioritise Three Key Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2484865486","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484865486?lang=en_us&edition=fundamental","pubTime":"2024-11-18 05:46","pubTimestamp":1731880013,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nFWN3MN0C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-06","defaultRemindTime":1725494400000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-20","payableDate":"2024-09-06","currency":"AUD","dateTimestamp":1725458400000,"payDate":"2024-09-20"},{"date":"2024-08-29","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724889600000,"name":null,"time":"","dateTimestamp":1724853600000,"actualEps":null},{"date":"2024-02-22","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":"2023-08-29","type":"dividend","market":"AU","newRecordDate":"2023-09-06","defaultRemindTime":1693872000000,"name":"Clinuvel Pharmaceuticals Ltd","recordDate":"2023-09-20","payableDate":"2023-09-06","currency":"AUD","dateTimestamp":1693836000000,"payDate":"2023-09-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}]}}